Docetaxel Plus Carboplatin Versus Epirubicin Plus Cyclophosphamide Followed by Docetaxel as Adjuvant Treatment in Triple-negative Breast Cancer
Observational
Observational Model: Case Control, Time Perspective: Prospective
Disease Free Survival (DFS) of 5 years
local recurrence, distant metastasis, the secondary primary malignancy
5 years after mastectomy
No
Peng Yuan, MD
Principal Investigator
Chinese Academy of Medical Sciences
China: Ministry of Health
CH-BC-007
NCT01150513
June 2010
June 2020
Name | Location |
---|